DNAY - Earnings announcements

-- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million to $25 million for the full year fiscal 2022 SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:DNAY), a company enabling customers to accelerate the reading and writing of biology, today reported financial results and business highlights for the third quarter ended September 30, 2022. "We are continuing to execute to our plan of being the leader in benchtop automation for synthetic biology, multiomics and next gen sequencing," said Todd R. Nelson, Ph.D., CEO and Founder of Te

SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (NASDAQ:DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes. In conjunction with the release, management will host a conference call the same day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live audio webcast can be accessed via the Investors section of Telesis Bio's website at www.codexdna.com. The conference call can be accessed by registering at the following link: https://register.veve

SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended June 30, 2022. Recent HighlightsContinued execution across all areas of the growth strategy: Increased total revenue by 98% over prior year periodGrew revenue by 44% on an organic basis year over year, excluding contributions from Eton Bioscience acquisitionDelivered solid growth in BioXp 3250 instrument placementsExperienced record high BioXp kit revenues, driven by growth in gene fragments, cloning, and DNA library kitsLaunched MyBioXperience, a new e-commerce solution, which dramatically sim

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its second quarter 2022 financial results on Tuesday, August 9, 2022, after the market closes. In conjunction with the release, management will host a conference call on Tuesday, August 9, 2022, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live audio webcast can be accessed via the Investors section of Codex DNA's website at www.codexdna.com. The conference call can be accessed by registering at the following link: https://regi

SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the first quarter ended March 31, 2022. "In the first quarter of 2022, we delivered robust revenue growth across our product portfolio," said Todd R. Nelson, PhD, CEO of Codex DNA. "With a strong global team, an expanding commercial presence, and groundbreaking enzymatic DNA synthesis technologies in development, we are in an excellent position to deliver on our mission to allow more customers to design and build synthetic DNA to address some of humanity's biggest challenges." Recent HighlightsContinued to execute in al

SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its first quarter 2022 financial results on Tuesday, May 10, 2022, after the market closes. In conjunction with the release, management will host a conference call on Tuesday, May 10, 2022, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live audio webcast can be accessed via the Investor section of the Company's website at www.codexdna.com. The conference call can be accessed by dialing (888) 705-0127 (domestic) or (409) 937-888

SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided financial guidance for 2022. "Codex DNA's first year as a publicly traded company was successful and productive, as we achieved significant financial and operational objectives," said Todd R. Nelson, PhD, CEO of Codex DNA. "We also took a number of critical steps in the fourth quarter to lay the foundation for the next phase of our growth, which included signing a substantial early access collaboration and licensing agreement with Pfizer, closing a highly

SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its fourth quarter 2021 financial results on Tuesday, March 22, 2022, after the market closes. In conjunction with the release, management will host a conference call on Tuesday, March 22, 2022, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live audio webcast can be accessed via the Investor section of the Company's website at www.codexdna.com. The conference call can be accessed by dialing (888) 705-0127 (domestic) or (409)

SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the third quarter ended September 30, 2021. "Our passion for innovation and vision to accelerate the creation of novel, synthetic biology-enabled solutions are what drives us every day," said Todd R. Nelson, PhD, CEO of Codex DNA. "This passion is reflected in the outstanding progress we've made in our innovative enzymatic DNA synthesis program and other R&D initiatives. In addition, we had a record quarter of BioXp™ system unit and kit sales, and we announced a highly strategic acquisition of Eton Bioscience, which b

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its third quarter 2021 financial results on Tuesday, November 9, 2021, after the market closes. In conjunction with the release, management will host a conference call on Tuesday, November 9, 2021, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live audio webcast can be accessed via the Investor section of the Company's website at www.codexdna.com. The conference call can be accessed by dialing (888) 705-0127 (domestic) or (409)

SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), the pioneer in automated benchtop synthetic biology systems, today announced that it will release its second quarter 2021 financial results on Tuesday, August 10, 2021. Company management will host a conference call on Tuesday, August 10, 2021, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights. The press release and live audio webcast can be accessed via the Investor section of the Company's website at www.codexdna.com. The conference call can be accessed by dialing (888) 705-0127 (domestic) or (409) 937-8880 (international) and referring to c